Strong Data Met a Skeptical Tape

On June 1, the French clinical-stage biotech announced topline results from its Phase 3 ABTECT maintenance trial of obefazimod, a first-in-class oral miR-124 enhancer for moderately to severely active ulcerative colitis. The numbers impressed by any standard. At Week 44, the 25 mg dose delivered clinical remission in 50.8% of patients, while the 50 mg dose reached 51.3% -- both towering over the 10.4% placebo rate, the lowest ever reported in a Phase 3 UC maintenance re-randomization trial. Moreover, both doses cleared every key secondary endpoint, including endoscopic remission and corticosteroid-free clinical remission, all with p-values below 0.0001.

CEO Marc de Garidel called the results “landmark,” and the company confirmed it will file a U.S. New Drug Application in late Q4 2026. In addition, Abivax expects Phase 2b Crohn’s disease data by mid-2027 and holds roughly EUR492 million in cash, enough runway into late 2027.

Yet investors sold first and asked questions later. Despite the headline win, the stock plunged about 23% in after-hours trading, then cratered another 40% the following session -- collapsing from nearly $130 to the low $70s in two days.

Why the Market Punished a Winner

The culprit sat deep in the safety tables. The 50 mg arm reported a handful of malignancies -- one case each of prostate cancer, breast cancer, and colonic dysplasia, plus four non-melanoma skin cancers -- while the 25 mg and placebo arms showed almost none. Investigators judged the solid-tumor cases unrelated to treatment and noted no organ-specific clustering. Nevertheless, traders feared the FDA might see a dose-dependent pattern, raising the specter of label warnings or regulatory friction.

Consequently, the analyst community split sharply. Wedbush flagged the malignancy imbalance and cut its target to $90, even while upgrading the stock from Underperform to Neutral. Similarly, Morgan Stanley trimmed its target from $145 to $132, though it compared obefazimod’s efficacy favorably to AbbVie’s Rinvoq. On the other side, Citizens raised its target to $187 and reiterated an Outperform rating, arguing the remission rates beat expectations and that its own read of the data showed no clear malignancy signal. Truist, meanwhile, held its Buy rating and warned that volatility will likely stay elevated into the Q4 NDA filing.

The Rebound -- and What Comes Next

By Wednesday, bargain hunters took control. Shares surged to $90.15, up 24.3%, as investors reconsidered whether a 40-point placebo-adjusted remission benefit justified a stock trading far below consensus targets near $147. The bounce also reflected context: Abivax’s open-label extension data show durable remission and a favorable safety profile across up to seven years of exposure.

Going forward, three catalysts will decide the story. First, the NDA filing in late Q4 2026 will test how regulators weigh the safety tables. Second, full trial data at upcoming medical congresses could either ease or amplify the malignancy debate. Third, the mid-2027 Crohn’s readout could expand the franchise well beyond ulcerative colitis.

The Takeaway

Abivax proves that in biotech, great data does not guarantee a great chart. Ultimately, the company delivered one of the strongest UC maintenance results on record; however, a few adverse-event lines overwhelmed the headline numbers for two trading sessions. For issuers and investors alike, the episode underscores a hard truth: how a company frames its safety data can matter as much as the efficacy it celebrates.

About Abivax

At Abivax, Their Mission Is to Harness the Power of microRNA Biology to Create Transformative Treatments for Patients in Need. To find out more investor relations information about Abivax please visit www.ir.abivax.com.

.